SML3594

Masitinib

≥98% (HPLC)

• Sinônimo(s): 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, AB1010
• Fórmula empírica (Notação de Hill): C₂₈H₃₀N₆OS
• Número CAS: 790299-79-5
• Peso molecular: 498.64
• Número MDL: MFCD09954132
• Código UNSPSC: 12352200
• NACRES: NA.77

Propriedades

• Nível de qualidade: 100
• Ensaio: ≥98% (HPLC)
• forma: powder
• cor: white to beige
• solubilidade: DMSO: 2 mg/mL, clear
• temperatura de armazenamento: 2-8°C
• cadeia de caracteres SMILES: CC1=CC=C(NC(C2=CC=C(CN3CCN(C)CC3)C=C2)=O)C=C1NC4=NC(C5=CN=CC=C5)=CS4
• InChI: 1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)
• chave InChI: WJEOLQLKVOPQFV-UHFFFAOYSA-N

Descrição

Ações bioquímicas/fisiológicas

Masitinib is a protein tyrosine kinase inhibitor that selectively targets stem cell factor receptor c-kit in particular and also PDGFRalpha/beta and Lyn. It is more potent and selective for c-kit than imatinib (Gleevec). Masitinib has antineoplastic and anti-inflammatory activity. It inhibits the survival, migration and activity of mast cells, key components of the inflammation response. It is used to treat mast cell tumors in dogs and is in clinical trials for human use in rheumatoid arthritis, asthma, and as an adjuct therapy for Alzheimer′s disease.

Informações de segurança

• Pictogramas: GHS08,GHS07
• Palavra indicadora: Warning
• Frases de perigo: H302,H361d,H373
• Declarações de precaução: P202 - P260 - P264 - P280 - P301 + P312 - P308 + P313
• Classificações de perigo: Acute Tox. 4 Oral - Repr. 2 - STOT RE 2
• Código de classe de armazenamento: 11 - Combustible Solids
• Classe de risco de água (WGK): WGK 3
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable